From Wikipedia, the free encyclopedia
ICI-118,551
Names
IUPAC name
3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol
Identifiers
ChEMBL
MeSH
ICI+118551
UNII
CC1=C2CCCC2=C(C=C1)OCC(C(C)NC(C)C)O
Properties
C17 H27 NO2
Molar mass
277.402 g/mol
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
ICI-118,551 is a selective
β2 adrenergic receptor (adrenoreceptor)
antagonist or
beta blocker .
[1]
[2] ICI binds to the β2 subtype with at least 100 times greater
affinity than
β1 or
β3 , the two other known subtypes of the beta adrenoceptor.
[3]
[4] The compound was developed by
Imperial Chemical Industries , which was acquired by
AkzoNobel in 2008.
ICI-118,551 has no known therapeutic use in humans although it has been used widely in research to understand the action of the β2 adrenergic receptor, as few other specific antagonists for this receptor are known.
[5] ICI-118,551 has been used in pre-clinical studies using murine models.
[6]
[7]
[8] When dissolved in
saline , the compound crosses the
blood–brain barrier . Common systemic doses used in rodent research are 0.5 or 1 mg/kg although efficacy has been demonstrated at doses as low as 0.0001 mg/kg (100 ng/kg) in
rhesus monkeys .
[9] Doses up to 20 mg/kg have been used without toxicity. At room temperature in saline, the ICI 118,551 hydrochloride is soluble to at least 2.5 mg/mL.
References
^ Hillman KL, Doze VA, Porter JE (August 2005). "Functional characterization of the beta-adrenergic receptor subtypes expressed by CA1 pyramidal cells in the rat hippocampus". The Journal of Pharmacology and Experimental Therapeutics . 314 (2): 561–7.
doi :
10.1124/jpet.105.084947 .
PMID
15908513 .
S2CID
12446381 .
^ Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M (2008). "A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors". Journal of Pharmacological and Toxicological Methods . 58 (3): 189–97.
doi :
10.1016/j.vascn.2008.06.003 .
PMID
18652905 .
^ Mauriège P, De Pergola G, Berlan M, Lafontan M (May 1988).
"Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists" . Journal of Lipid Research . 29 (5): 587–601.
doi :
10.1016/S0022-2275(20)38502-3 .
PMID
2900871 .
^ Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (September 1989). "Molecular characterization of the human beta 3-adrenergic receptor". Science . 245 (4922): 1118–21.
Bibcode :
1989Sci...245.1118E .
doi :
10.1126/science.2570461 .
PMID
2570461 .
^ Ruffolo Jr RR, ed. (1995). Adrenoceptors: Structure, Function. and Pharmacology . Luxembourg: Harwood Academic Publisher.
^ Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, et al. (21 December 2017).
"Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice" . Oncoimmunology . 7 (3): e1405205.
doi :
10.1080/2162402X.2017.1405205 .
PMC
5790362 .
PMID
29399407 .
^ Branca C, Wisely EV, Hartman LK, Caccamo A, Oddo S (December 2014).
"Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease" . Neurobiology of Aging . 35 (12): 2726–2735.
doi :
10.1016/j.neurobiolaging.2014.06.011 .
PMC
4252846 .
PMID
25034342 .
^ Nagaraja S, Iyer S, Liu X, Eichberg J, Bond RA (July 1999).
"Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic beta2-adrenoceptor activation" . British Journal of Pharmacology . 127 (5): 1099–104.
doi :
10.1038/sj.bjp.0702645 .
PMC
1566118 .
PMID
10455254 .
^ Ramos BP, Arnsten AF (March 2007).
"Adrenergic pharmacology and cognition: focus on the prefrontal cortex" . Pharmacology & Therapeutics . 113 (3): 523–36.
doi :
10.1016/j.pharmthera.2006.11.006 .
PMC
2151919 .
PMID
17303246 .
α1
Agonists Antagonists
Abanoquil
Ajmalicine
Alfuzosin
Anisodamine
Anisodine
Atiprosin
Atypical antipsychotics (e.g.,
brexpiprazole ,
clozapine ,
olanzapine ,
quetiapine ,
risperidone )
Benoxathian
Beta blockers (e.g.,
adimolol ,
amosulalol ,
arotinolol ,
carvedilol ,
eugenodilol ,
labetalol )
Buflomedil
Bunazosin
Corynanthine
Dapiprazole
Domesticine
Doxazosin
Ergolines (e.g.,
acetergamine ,
ergotamine ,
dihydroergotamine ,
lisuride ,
nicergoline ,
terguride )
Etoperidone
Fenspiride
Hydroxyzine
Indoramin
Ketanserin
L-765,314
mCPP
Mepiprazole
Metazosin
Monatepil
Moxisylyte
Naftopidil
Nantenine
Neldazosin
Niaprazine
Niguldipine
Pardoprunox
Pelanserin
Perlapine
Phendioxan
Phenoxybenzamine
Phentolamine
Phenylpiperazine
antidepressants (e.g.,
hydroxynefazodone ,
nefazodone ,
trazodone ,
triazoledione )
Piperoxan
Prazosin
Quinazosin
Quinidine
Silodosin
Spegatrine
Spiperone
Talipexole
Tamsulosin
Terazosin
Tiodazosin
Tolazoline
Tetracyclic antidepressants (e.g.,
amoxapine ,
maprotiline ,
mianserin )
Tricyclic antidepressants (e.g.,
amitriptyline ,
clomipramine ,
doxepin ,
imipramine ,
trimipramine )
Trimazosin
Typical antipsychotics (e.g.,
chlorpromazine ,
fluphenazine ,
loxapine ,
thioridazine )
Urapidil
WB-4101
Zolertine
α2
Agonists Antagonists
1-PP
Adimolol
Amesergide
Aptazapine
Atipamezole
Atypical antipsychotics (e.g.,
asenapine ,
brexpiprazole ,
clozapine ,
lurasidone ,
olanzapine ,
paliperidone ,
quetiapine ,
risperidone ,
zotepine )
Azapirones (e.g.,
buspirone ,
gepirone ,
ipsapirone ,
tandospirone )
BRL-44408
Buflomedil
Cirazoline
Efaroxan
Esmirtazapine
Fenmetozole
Fluparoxan
Idazoxan
Ketanserin
Lisuride
mCPP
Mianserin
Mirtazapine
NAN-190
Pardoprunox
Phentolamine
Phenoxybenzamine
Piperoxan
Piribedil
Rauwolscine
Rotigotine
Setiptiline
Spegatrine
Spiroxatrine
Sunepitron
Terguride
Tolazoline
Typical antipsychotics (e.g.,
chlorpromazine ,
fluphenazine ,
loxapine ,
thioridazine )
Yohimbine
β